Outcome of Board Meeting
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Viyash Scientific Limited's Board approved audited financial results for Q4 and FY26 ended March 31, 2026. Standalone revenue for FY26 was ₹13,820.60 million with PAT of ₹758.70 million, while consolidated revenue was ₹34,203.10 million with PAT of ₹1,054.00 million (vs ₹157.70 million restated in FY25). The Board approved a large grant of 1,30,98,000 stock options to employees under the new ESOP Scheme 2026. The Composite Scheme of Amalgamation with Viyash Life Sciences Private Limited and subsidiaries became effective on December 16, 2025, significantly expanding the consolidated entity. No dividend was recommended for FY25-26 to conserve resources. The auditors issued an unmodified opinion on both standalone and consolidated results.
Strong improvement in profitability year-on-year, boosted by the amalgamation. However, no dividend may disappoint income-focused investors. The large ESOP grant aligns employee interests with shareholders but could have minor dilution impact.